Clinical application of tadalafil in dogs with pulmonary hypertension: a retrospective study
Abstract
Pulmonary hypertension (PH) is characterized by abnormally increased pressure within the pulmonary vasculature. Phosphodiesterase type 5 (PDE5) inhibitors are commonly used to manage PH, and tadalafil, a PDE5 inhibitor with a longer half-life than sildenafil, has rarely been investigated in veterinary medicine. This retrospective study analyzed medical records of dogs treated with tadalafil at the Veterinary Medical Teaching Hospital of Jeju National University between January 2021 and July 2023. Eleven dogs tentatively diagnosed with PH received tadalafil at an initial dosage of 1 mg/kg once daily and were monitored for over 4 weeks. Efficacy and adverse effects were evaluated based on history and physical examination findings. Ten dogs had previously received sildenafil, while one dog was treated with tadalafil as first‐line therapy. Nausea occurred in one case. Seven of 11 dogs achieved at least partial remission, whereas 4 showed no improvement. Notably, 8 dogs (72.7%) were receiving concomitant medications targeting the underlying diseases causing PH, which may have contributed to symptom improvement and influenced clinical outcomes. Thus, although tadalafil at 1 mg/kg once daily was generally well tolerated and appeared to provide acceptable control of PH, its efficacy should be interpreted cautiously given the small sample size. It may be particularly beneficial when the underlying diseases causing PH are adequately managed with concomitant therapies, within the…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- Therapeutic Potential of Mesenchymal Stem Cells (MSCs) and MSC-Derived Extracellular Vesicles for the Treatment of Spinal Cord Injury
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.